Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03079583
Other study ID # ZARI_1_trail
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 1, 2018
Est. completion date April 25, 2019

Study information

Verified date July 2021
Source Swiss Federal Institute of Technology
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To assess the efficacy of the zinc biofortified rice on plasma zinc concentrations in infants from a rural area of Bangladesh.


Description:

Rationale: Around the world and estimated 30% of the population is at risk of Zinc deficiency, mainly due to monotonous plant base diets and the poor bioavailability of this sources. One staple food crop which is low in zinc content is rice. Therefore, zinc deficiency is highly common in Asia. Zinc plays a major role in child growth and neurobehavioral development. Furthermore, it is linked to infection control and normal immune response. One way to add extra zinc to someone's diet is zinc bio fortification of staple crops, which can be a cost saving sustainable approach to improve zinc nutrition. However, data on long-term intake of biofortified crops with zinc is scarce and efficacy of newly developed rice crops high in zinc are not well known. Objective: The objective is to assess the efficacy of a newly developed zinc biofortified rice variety on plasma zinc concentrations in children in a rural area of Bangladesh when compared to their controls in a 9 month randomized controlled trial (RCT). Study design: A double randomized control trial. Study population: Stunted children whom are zinc deficient at start of the study intervention determined by plasma zinc levels <9.9 µmol/L. Main study parameters/endpoints: The difference in zinc status between the intervention and control group expressed in blood plasma zinc levels. Plasma zinc will be measured 4 times during the intervention period. Besides plasma zinc other zinc biomarkers will be tested for their usefulness.


Recruitment information / eligibility

Status Completed
Enrollment 520
Est. completion date April 25, 2019
Est. primary completion date April 25, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 12 Months to 36 Months
Eligibility Inclusion Criteria: - 12-36 months of age (at baseline assessment) - Low plasma Zn concentration (<10.71 µmol/L) - Marginally stunted (height for age Z-score <-1.75) - The informed consent form has been read and signed by the caregiver (or has been read out to the caregiver in case of illiteracy) Exclusion Criteria: - Severe Anemia (Hb< 70 g/L) - Chronic or acute illness or other conditions that in the opinion of the Principle Investigator (PI) or co-researchers would affect Zn metabolism or would render the participant unable to comply with the protocol (based on self-reporting or diagnosed during screening) - Participants taking part in other studies requiring the drawing of blood - Not planning long-term residence in study site - Regular intake (>2 days) of iron-containing mineral and vitamin supplements or fortified foods within the last 2 months - Chronic use of drugs that affect the metabolism of Zn, including reducing absorption or increasing excretion; e.g., tuberculosis medications (ethambutal and isoniazides), drugs used as treatment for entamoeba hystolica (diiodohydroxyquin), drugs that reduce stomach acidity (H2 blockers and proton pump inhibitory), antidepressants (nialamide and socarboxazid), anti-inflammatory drugs (corticosteroids), diuretics (thiazides).

Study Design


Intervention

Dietary Supplement:
Intervention-group
Biofortified Rice is grown by foliar Zn application
Control-group
Control Rice with normal zinc levels

Locations

Country Name City State
Bangladesh BRACU, Bangladesh Dhaka
Switzerland Swiss Federal Institute of Technology (ETH) Zurich

Sponsors (3)

Lead Sponsor Collaborator
Swiss Federal Institute of Technology BRAC University, HarvestPlus

Countries where clinical trial is conducted

Bangladesh,  Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary plasma zinc Change of plasma zinc values from baseline to endpoint and 2 times within study period 4 collection points in total. 2 fixed at start and end of intervention (week 1&36, T=1,4). 2 sparse random sampling points (RSP) in-between T=1-4. First RSP between 2-5 months (week 5-20 T=2). Second RSP between 5-8 months (week 21-32,T=3).
Secondary Inflammatory markers C reactive protein (CRP),alpha1-acid glycoprotein (AGP) 4 collection points in total. 2 fixed at start and end of intervention (week 1&36, T=1,4). 2 sparse random sampling points (RSP) in-between T=1-4. First RSP between 2-5 months (week 5-20 T=2). Second RSP between 5-8 months (week 21-32,T=3).
Secondary Length Length (in cm) measurement for anthropometric (HAZ-scores). 4 collection points in total. 2 fixed at start and end of intervention (week 1&36, T=1,4). 2 sparse random sampling points (RSP) in-between T=1-4. First RSP between 2-5 months (week 5-20 T=2). Second RSP between 5-8 months (week 21-32,T=3).
Secondary Weight Weight (in kg) measurement for anthropometric (HAZ-scores). 4 collection points in total. 2 fixed at start and end of intervention (week 1&36, T=1,4). 2 sparse random sampling points (RSP) in-between T=1-4. First RSP between 2-5 months (week 5-20 T=2). Second RSP between 5-8 months (week 21-32,T=3).
Secondary Morbidity diarrhea and disease episodes will be recorded weekly throughout the study Fixed assessment once a week for every participant throughout the intervention period (week 1-36).
Secondary FADS analyses FADS plasma analyses for zinc biomarker determination Secondary analyses of collected plasma samples, in subset of participants (75 children from each group, random selected, matched baseline and endpoint samples)
Secondary Iron status Plasma ferritin 4 collection points in total. 2 fixed at start and end of intervention (week 1&36, T=1,4). 2 sparse random sampling points (RSP) in-between T=1-4. First RSP between 2-5 months (week 5-20 T=2). Second RSP between 5-8 months (week 21-32,T=3).
Secondary Iron status Hemoglobin 4 collection points in total. 2 fixed at start and end of intervention (week 1&36, T=1,4). 2 sparse random sampling points (RSP) in-between T=1-4. First RSP between 2-5 months (week 5-20 T=2). Second RSP between 5-8 months (week 21-32,T=3).
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03353662 - Sub Regional Micronutrient Survey in Ethiopia
Completed NCT02126293 - Correction of Zinc Deficiency in Children With Chronic Kidney Disease and Kidney Transplant Phase 3
Terminated NCT01472211 - Water-based Zinc Intervention Trial in Zinc Deficient Children Phase 0
Completed NCT01061307 - An Efficacy Trial of Iron, Zinc and Vitamin A Fortified Rice in Children in Satun, Thailand Phase 0
Recruiting NCT03421314 - Effect of Zinc and Selenium Supplementation on HIV+ Individuals on Antiretroviral Treatment. N/A
Completed NCT02292303 - Clinical Trial to Determine the Bioavailability of Three Different Zinc Preparations N/A
Completed NCT02241330 - Efficacy of Zn Biofortified Wheat in Improving Zn Status in Indian School Children With Low Zn Status N/A
Completed NCT01221129 - Zinc and the Synthesis of Zinc Binding Proteins (Protocol B) N/A
Completed NCT04632771 - Nutritional Status and Bouillon Use in Northern Ghana
Recruiting NCT05236374 - Effects of Daily Beef Intake, as a Component of a Heart-Healthy Diet on Cellular Zinc N/A
Completed NCT02760095 - Effects of EED on Zn Absorption and Retention in Children From a Standard Dose
Completed NCT02758444 - Effects of EED on Zn Absorption and Retention in Children From a MNP N/A
Completed NCT02233764 - Effect of Iron/Zinc-Biofortified Pearl Millet on Growth and Immunity in Children Aged 12-18 Months in India N/A
Recruiting NCT05527899 - Zinc Intervention in Elderly for Prevention of Pneumonia Phase 2/Phase 3
Terminated NCT04983667 - Zinc-AA Supplementation During Pregnancy & Lactation to Assess Effects on ASD Prevalence in Offspring N/A
Completed NCT03293641 - Zinc Supplementation in Children With Sickle Cell Disease in Western Kenya N/A
Completed NCT05778383 - Zinc Supplementation Impact in Acute COVID-19 Clinical Outcomes Phase 4
Completed NCT04559152 - Zinc Supplementation During Pregnancy: Analysis of Maternal Serum Zinc, Cord Blood Osteocalcin and Neonatal Birth Length N/A
Completed NCT01062347 - A Novel Bio-marker of Zinc Status Phase 1
Recruiting NCT05085834 - Zinc Effect on Inflammation and Cardiovascular Risk in HIV Early Phase 1